Harvard researchers develop predictive model for cirrhosis outcomes

Researchers from Harvard have developed a predictive model, called MELD-Plus, capable of identifying patients at high-risk for developing negative outcomes following a hospital admission for cirrhosis. Findings were published in PLOS One.

The ability to identify and predict negative outcomes after hospital admission could reduce readmission and give healthcare providers a chance to personalize treatment plans. To develop the post-discharge mortality prediction model, researchers analyzed 314,292 patients from 1992 to 2010 who received care for cirrhosis at Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital (BWH). From the sample population, 68 variables from patient electronic health records (EHRs) were included in measuring patient risk.

Overall, nine variables that were most effective in predicting 90-day mortality were included in MELD-Plus. In testing the models’ predictive accuracy, researchers applied MELD-Plus to 18 million cirrhosis-related admissions from 2010 to 2015. Results showed that the model was able to improve on current predictive methods for 90-day and one-year outcomes.

“We developed a new risk score, MELD-Plus that accurately stratifies the short-term mortality of patients with established cirrhosis, following a hospital admission,” concluded first author Uri Kartoun and colleagues. “Our findings demonstrate that using a small set of easily accessible structured variables can help identify novel predictors of outcomes in cirrhosis patients and improve the performance of widely used traditional risk scores.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”